All News

child.guttate.psoriasis

Kids With Psoriasis Maintained with Long Term IL-17A Inhibitor

d MedPage Today

Pediatric patients with moderate-to-severe plaque psoriasis obtained significant improvement in disease status for as long as 2 years with the interleukin (IL)-17A inhibitor ixekizumab (Taltz), long-term follow-up from a randomized trial showed.

Read Article
uric%20acid.crystals.gout_.JPG

No Benefit to More Intensive Urate Lowering in Gout

d Jack Cush, MD

While treat-to-target (T2T) is commonly advocated in gout management, it is unknown if T2T (or more intensive T2T) may result in less bony erosions in gout.

Read Article
virtual online learning home office zoom

Consensus Best Practices for Virtual Care in Rheumatology

d Jack Cush, MD

The Canadian Rheumatology Association’s (CRA) Telehealth Working Group (TWG) has developed a series of best practice statements for the virtual care in adult and pediatric rheumatology patients.

Read Article
Young,doctor,mask

ACR Fellow Training Subcommittee Report on Pandemic Experiences

d Jack Cush, MD

Arthritis & Rheumatology has publish an ACR Subcommittee report on how the COVID-19 pandemic affected fellows and their training. 

Read Article
dementia,brain

Is Alzheimer's Risk Lower With TNF Inhibitors?

d MedPage Today

Tumor necrosis factor (TNF) inhibitors for rheumatoid arthritis were linked with a lower risk of Alzheimer's disease and related dementia, but only in people with cardiovascular disease, data from the DREAM (Drug Repurposing for Effective Alzheimer's Medicines) study showed.

Read Article
QD Clinic - PsA Lessons from the Clinic LFT Elevations may be considered differently in PsA patients QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022 https://t.co/dCaWx5OTda https://t.co/bRTVqQ4ZJj

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Laura Coates discusses Precision Medicine in PsA. https://t.co/ttKHZDGjyC https://t.co/XwahihZyGH

Links:

Dr. John Cush RheumNow ( View Tweet)
The value of COVID Vaccine after COVID infection - Vax Effx after COVID=445% after 2 doses & 58% after booster during Delta COVID. During Omicron, 35% effect after 2 doses and 68% after a booster dose - best protection conferred by booster https://t.co/VXi70r2nS3 https://t.co/Oeuet3pudD

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - PsA Lessons from the Clinic Reasons why PsA patient can lose biologic efficacy and what to do about it QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022 https://t.co/Bxy1G68rU9 https://t.co/CLe9SHfRQJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Combined Clinics for PsA Rheums and derms have long worked together in the management of our patients, but the idea of directly collaborating in a single clinic space was novel at the time. Over the years, it has become my favorite clinic of the week. https://t.co/uY1mZtlvaV https://t.co/5AZ2z2kSVG

Links:

Dr. John Cush RheumNow ( View Tweet)
Comparison of Tofa, ADA, PBO in OPAL #PSA studies - median time to HAQ response better for Tofa & ADA (30d) vs PBO (>112d), but Tofa had faster Fatigue response (31 vs 90+D). MDA response time same between Tofa v ADA #PSAlways https://t.co/f48Of7bEjN https://t.co/KvfQUbLwCH

Links:

Dr. John Cush RheumNow ( View Tweet)
NPF COVID-19 report from AAD mtg shows #PSA pts on systemic Rx were not at risk of hospitalization or severe COVID-1 based on US claims data. Also TNFi, IL-17, IL-23 Rx not affect on Vax Ab responses; less hosp (36%) w/ TNFi https://t.co/ekvu0mMvrn https://t.co/Qogm1Vx5hF

Links:

Dr. John Cush RheumNow ( View Tweet)
How long does a good response last to a biologic? How and When to distinguish between flares and intercurrent illness. QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022 https://t.co/ZIWQysY5dd https://t.co/RZrS6FfUTV

Links:

Dr. John Cush RheumNow ( View Tweet)
SLE study from BC, Canada shows that among 3062 incident #SLE patients 96% received antimalarial (AM) Rx with only 40% adherent. Over a 6.4 yr F/U, 242 (8%) died. AM adherence was assoc w/ a 71% and 83% lower risk of death https://t.co/S9LsDaSZNx https://t.co/lFWZJTh367

Links:

Dr. John Cush RheumNow ( View Tweet)
Ixekizumab in 1401 #PSA pts w/ 2248 Pt-Yrs exposure showed Serious AE in 134 pts. Most common AEs were nasopharyngitis & URI. Incidence of SAE (≤1.2/100PY), cancer (0.7/100PY), IBD (0.1/00PY), depression (1.6/100PY) were low. #PSAlways https://t.co/YGGj4XCQDM

Links:

Dr. John Cush RheumNow ( View Tweet)

Retrospective study of 1144 consecutive inflammatory myositis (IIM) pts shows a 2.3% risk of venous thrombolic events. 54% of VTE occurred within 6 mos of IIM Dx. Predictors included malignancy, infection, longer steroid use , higher Dz activity https://t.co/DCH4Iuy2FS https://t.co/uNc6i6L7JJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Cell has a novel analysis using single-cell analysis of skin/blood from 56 controls & 97 diffuse systemic sclerosis pts, finding stromal abnormalities in LGR5+-scleroderma-assoc fibroblasts (ScAFs). ScAFs are decreased early & progressively https://t.co/Khxejd1fnq https://t.co/OrMAJnPTZt

Links:

Dr. John Cush RheumNow ( View Tweet)
ArthritisPower study of 332 #PsA pts finds patients are most bothered by joint pain, MSK pain & fatigue. Patients prefer oral, QD meds; 3/4 want Rx that improved joints vs skin; and would prefer to avoid MTX https://t.co/WYqWgoimOT https://t.co/RgGeCKrpT1

Links:

Dr. John Cush RheumNow ( View Tweet)
2020 Pt preferences survey- 137 #PsA pts most took TNFi (30%), IL-17i (20%), MTX (10%). From 2018 to 2020 a signif incr in IL-17i & PDE4 inhib. Pts want Rx for damage (80%), ADL (71%), & pain (70%) https://t.co/2dyIuQubh5 https://t.co/sFbtRj0Lbv

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Deucravacitinib, TYK2 inhib, studied in phase II trial 203 active PsA pts randomised to PBO, or DEUC 6 mg or 12 mg qd. At wk 16 ACR-20 responses were significantly higher with DEUC 6mg (53%, p=0.0134) and 12 mg (63%, p=0.0004) vs PBO. https://t.co/UOPteZY0g8 https://t.co/Xw3ZSPWeE0

Links:

Dr. John Cush RheumNow ( View Tweet)
×